Effects of rottlerin on silica-exacerbated systemic autoimmune disease in New Zealand mixed mice

Jared M. Brown, Corbin M. Schwanke, Mark A. Pershouse, Jean C. Pfau, and Andrij Holian

Department of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, Missoula, Montana

Submitted 17 February 2005 ; accepted in final form 18 July 2005


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Environmental crystalline silica exposure has been associated with formation of autoantibodies and development of systemic autoimmune disease, but the mechanisms leading to these events are unknown. Silica exposure in autoimmune-prone New Zealand mixed (NZM) mice results in a significant exacerbation of systemic autoimmunity as measured by increases in autoantibodies and glomerulonephritis. Previous studies have suggested that silica-induced apoptosis of alveolar macrophages (AM) contributes to the generation of the autoantibodies and disease. Rottlerin has been reported to inhibit apoptosis in many cell types, possibly through direct or indirect effects on PKC{delta}. In this study, rottlerin reduced silica-induced apoptosis in bone marrow-derived macrophages as measured by DNA fragmentation. In NZM mice, RNA and protein levels of PKC{delta} were significantly elevated in AM 14 wk after silica exposure. Therefore, rottlerin was used to reduce apoptosis of AM and evaluate the progress of silica-exacerbated systemic autoimmune disease. Fourteen weeks after silica exposure, NZM mice had increased levels of anti-histone autoantibodies, high proteinuria, and glomerulonephritis. However, silica-instilled mice that also received weekly instillations of rottlerin had significantly lower levels of proteinuria, anti-histone autoantibodies, complement C3, and IgG deposition within the kidney. Weekly instillations of rottlerin in silica-instilled NZM mice also inhibited the upregulation of PKC{delta} in AM. Together, these data demonstrate that in vivo treatment with rottlerin significantly decreased the exacerbation of autoimmunity by silica exposure.

alveolar macrophage; apoptosis; protein kinase C{delta}


SILICA IS UBIQUITOUS in the environment as an abundant mineral found in rock, sand, and soil. Silicosis is an occupational disease resulting from acute or chronic high levels of silica exposure that leads to decreased pulmonary function and increased susceptibility to other diseases of the respiratory tract (2). Upon inhalation, silica is deposited in the alveolar spaces and ingested by alveolar macrophages (AM) (5). High exposures of silica have been reported to impair the clearance of silica particles, leading to accumulation of silica-laden macrophages within the lymphatics and interstitial spaces of the lung (5). Furthermore, focal injury of macrophages by silica at these sites has been reported to result in the release of silica particles and repeat triggering of the local inflammatory response (36, 37). Silicosis has also been associated with increased incidence of systemic autoimmune disease, such as systemic lupus erythematosus and scleroderma (25, 26, 39). Patients with silicosis have increased autoantibodies, immunoglobulins, and immune complexes (12). Although some of the enhanced humoral response could be attributed to a nonspecific adjuvant effect, the tendency toward select autoimmune diseases suggests a more specific effect. Using autoimmune-prone New Zealand mixed (NZM) mice, we have previously reported that silica exposure significantly exacerbates the progression of autoimmune disease (6). After silica exposure, NZM mice develop high levels of autoantibodies to nuclear antigen, including histones, as well as develop glomerulonephritis and pulmonary fibrosis within 14 wk (6).

Apoptosis has been reported to play a role in the initiation and progression of systemic autoimmune disease, and silica has been reported to induce a caspase-specific apoptotic response within AM (14, 15, 19, 21, 24, 30, 34). We have previously reported a possible role for apoptosis in the exacerbation of autoimmune disease in NZM mice (27). Autoantibodies from silica-exposed mice specifically recognize apoptotic cells, and there appears to be greater recognition of silica-induced apoptotic cells compared with live, necrotic, or cycloheximide-induced apoptotic cells (27).

PKC{delta} is a novel PKC family member that has been reported to play a role in the initiation of apoptosis in many cell types (3, 4, 22, 28, 32, 38). PKC{delta} is activated by diacylglycerol/phorbol esters in a calcium-independent manner as well as by phosphorylation and caspase cleavage (20). PKC{delta} is activated in neutrophils undergoing spontaneous apoptosis, in H2O2-induced apoptosis, TNF-{alpha}-induced apoptosis, Fas-mediated apoptosis, and asbestos-induced apoptosis of alveolar epithelial cells (3, 4, 22, 28, 32, 38). PKC{delta} has been reported to translocate to the nucleus and mitochondria after activation by the above-mentioned mechanisms, thereby inducing caspase activation (4, 16, 20). Rottlerin has been reported as an inhibitor of apoptosis mediated by PKC{delta} (4, 16, 17, 20). However, it remains controversial as to whether the inhibition of apoptosis by rottlerin is mediated directly or indirectly through PKC{delta}. The overall objective of this study was to test the hypothesis that in vivo treatment with rottlerin could significantly affect the exacerbation of systemic autoimmune disease by silica.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Mice. Male and female NZM 2410 mice were obtained from Taconic (Germantown, NY) and maintained in microisolation containers in accordance with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources, National Research Council. The animal room was set on 12-h dark/light cycles with food and water provided ad libitum. All protocols for the use of animals were approved by the University of Montana Institutional Animal Care and Use Committee.

Cells. BALB/c bone marrow-derived macrophages (BMDM) were generated for in vitro use. BALB/c mice were killed with a lethal injection of Nembutal (200 µl ip), and the femur bones were collected. Recovery of the bone marrow cells was done within a sterile hood, and the cells were flushed from the bones using a 25-gauge needle. The cells were counted and plated at 3 x 107 cells in 75-cm2 flasks. The cells were incubated overnight at 37°C. The non-adherent cells were then collected, allowing removal of stromal cells. The nonadherent cells were then replated in RPMI 1640/10% FCS and 10 ng/ml recombinant mouse macrophage colony-stimulating factor (R&D Systems, Minneapolis, MN). The cells were allowed to differentiate into macrophages for 5–7 days before use. Cell viability was determined to be >90% by trypan blue exclusion before treatments.

Apoptosis assay. Apoptosis was determined by DNA fragmentation in bone marrow-derived macrophages using a TiterTacs Assay (R&D Systems). The manufacturer's protocol was followed. Equal numbers of cells (1 x 105/well) were plated in a 96-well plate and allowed to adhere overnight. Silica was added for 8 h at 500 µg/ml with or without the addition of 1 µg/ml rottlerin 30 min prior. Nontreated cells were used as a negative control, and a nuclease-generated positive control was used. Experiments were repeated three times. The reported values are mean optical density (OD) values from each treatment.

Silica instillation. Silica (Min-U-Sil-5, with an average particle size of 1.5–2 µm) was obtained from Pennsylvania Glass Sand (Pittsburgh, PA) and was acid washed, dried, and determined to be free of endotoxin. At 6 wk of age, mice were instilled intranasally with either 30 µl of saline (n = 6) or 30-µl saline suspensions of 1 mg of crystalline silica (n = 6) or 500 µg of TiO2 (n = 6) as previously described. All mice received two instillations 2 wk apart. Control and experimental groups were matched for equal number of male and female mice. AM were collected at 14 wk for use in microarray experiments. A second cohort of mice was used to measure changes in protein levels of PKC{delta} and received 30 µl of saline (n = 4) or 30-µl saline suspensions of 1 mg of crystalline silica (n = 4) or 500 µg of TiO2 (n = 4). A third cohort of mice was used for in vivo inhibition of PKC{delta} using rottlerin (AG Scientific, San Diego, CA), a PKC{delta}-selective inhibitor (11, 17). Rottlerin was given at 10 µg/instillation and diluted in sterile saline; a volume of 30 µl was used for intranasal instillation. Mice received either saline (n = 5), silica (1 mg x 2 instillations) (n = 5), silica (1 mg x 2 instillations) plus rottlerin (10 µg/weekly instillation; n = 5), or rottlerin only (10 µg/weekly instillation; n = 5). Rottlerin was given intranasally 1 day before addition of saline or silica and then again with the instillation of saline or silica at 6 wk of age. Rottlerin was then given once a week until the mice were killed at 14 wk. The saline- and silica-only treated animals were given saline instillations once a week for 14 wk as a control instillation to match the rottlerin instillations. After 14 wk, a time point when the majority of silica-exposed mice developed autoimmune disease as measured by proteinuria and autoantibodies, the mice were killed with a lethal injection of Nembutal (200 µl ip), and blood was collected by cardiac puncture. Clotted blood was centrifuged, and serum was collected and frozen at –20°C until use. AM were harvested from the lung by bronchoalveolar lavage for generation of protein lysates for use in Western immunoblotting, and kidneys were removed and placed in Histochoice fixative (Amresco, Solon, OH).

RNA extraction and amplification. RNA was extracted from six mouse bronchoalveolar lavage samples per condition (saline, silica, or TiO2 treatment) using TRIzol (Invitrogen, Carlsbad, CA) with an extra chloroform extraction following the initial chloroform step to further remove organics from the final RNA product. Equal amounts of the resulting RNA from each sample within a condition were pooled and further purified and concentrated using RNeasy mini-preps (Qiagen, Valencia, CA). Production of amplified RNA (aRNA) was performed using a RiboAmp kit (Arcturus, Carlsbad, CA).

Microarray target labeling and hybridization. For each sample, 5 µg of aRNA and 10 µg of Universal Mouse Reference RNA were indirectly labeled with Alexa Fluor 647 or Alexa Fluor 555, respectively, using Superscript II (Invitrogen) reverse transcriptase according to the ARES DNA labeling kit protocol.

Labeled cDNA from reference RNA and aRNA were combined and hybridized overnight in a 25% formamide hybridization buffer to an inhouse cDNA microarray with ~1,200 different cDNA probes specific to mouse toxicology and immunology genes.

Microarray analysis. Hybridized arrays were scanned with an Axon GenePix 4000B laser slide scanner and visualized with GenePix Pro 4.0 software. Resulting result and image files were imported into GeneTraffic Duo Microarray Data Management and Analysis software (Iobion Informatics, La Jolla, CA) and normalized to a total 1:1 red to green ratio for the entire slide. Data were filtered based on replicate quality, signal intensity, and signal-to-background ratios of 1.2 or higher. An arbitrary cutoff of 1.5-fold up- or downregulation was used to determine genes of interest.

Histology. Kidneys were removed and routinely processed using an automated processor (ThermoShandon, Pittsburgh, PA). The kidneys were embedded in paraffin wax, sectioned 5 µm thick, and then collected on poly-L-lysine-coated slides (Sigma Chemical, St. Louis, MO). The kidney sections were boiled in a 0.01 M sodium citrate buffer for 10 min followed by washes in distilled water and PBS. The kidney sections were then blocked with 4% FBS in PBS. Goat anti-mouse IgG-FITC antibody (1:100; ICN Biomedicals, Irvine, CA) and goat anti-mouse C3-FITC (1:100, ICN Biomedicals) were added for 4 h for the detection of immune complexes and complement deposition. A goat anti-rat IgG antibody (1:100, ICN Biomedicals) was used as an isotype control. Samples were blinded and examined using a confocal microscope.

Urinary protein. Proteinuria was measured by Chemstrip 2 GP test strips as described by the manufacturer (Boehringer Mannheim Diagnostics, Indianapolis, IN). Milligram protein per deciliter was measured among groups following the provided scale (0 = negative; trace, 1+ = 30 mg/dl; 2+ = 100 mg/dl; 3+ = 500 mg/dl).

Detection of serum autoantibodies. Anti-histone autoantibodies were detected using an ELISA kit (Alpha Diagnostics, San Antonio, TX). Sera were diluted 100-fold before assay, and the manufacturer's protocol was followed. The reported values are mean OD values from each treatment group.

Western immunoblots. Western immunoblots were performed using lysates generated from AM collected by bronchoalveolar lavage. Lavage cells were collected and determined to be between 75 and 90% AM, and an equal number of cells were lysed using a 0.5% Nonidet P-40 detergent (Sigma) with freshly added complete protease inhibitors: 10 µg/ml pepstatin, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF (Roche, Indianapolis, IN). Samples were kept on ice during lysis and frozen immediately at –20°C until use. Protein concentrations of lysates were determined using a Bio-Rad protein assay (Bio-Rad, Hercules, CA), and equal concentrations of lysates were loaded onto Invitrogen 12% Nu-PAGE gels (Carlsbad, CA) followed by transfer onto nitrocellulose (Bio-Rad). Nitrocellulose blots were probed using an antibody to PKC{delta} (1:300; BD Transduction Laboratories, San Diego, CA). Purified PKC{delta} (Oxford Biomedical Research, Oxford, MI) was used as a positive control. Detection of antibody to PKC{delta} was performed using goat anti-mouse IgG-horseradish peroxidase (1:2,000; Jackson Immunoresearch, West Grove, PA). Detection of positive bands was done using enhanced chemiluminescence reagent (Amersham, Piscataway, NJ), and they were visualized using a VersaDoc imaging system (Bio-Rad). Densitometry was performed using Quantity One software (Bio-Rad) to quantitate differences between bands. Numbers reported are density [intensity (int)/mm2].

Statistical methods. Statistical analysis was done using the software package PRISM, version 3.03 (GraphPad, San Diego, CA). Differences among saline-, TiO2-, and silica-treated mouse groups were assessed using one-way ANOVA with Bonferroni posttest. Statistical differences in the development of proteinuria were determined by the nonparametric Kaplan-Meier log-rank comparison. All values are reported as means ± SE; P ≤ 0.05 was considered significant.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
PKC{delta} is upregulated in AM from silica-exposed NZM mice. Silica exposure has been reported to induce apoptosis in several cell types; however, the signaling cascade leading to the apoptotic response is not fully defined (9, 18, 34). Therefore, AM were collected from silica-exposed NZM mice to screen for changes in apoptotic genes using microarray technology. Using an inhouse microarray chip with 1,200 immunology and toxicology genes, we identified several genes involved in apoptosis that were upregulated 1.5-fold or higher after silica exposure (Table 1). Fourteen weeks after two instillations of 1 mg of silica, the RNA levels of PKC{delta} were elevated 1.5-fold compared with saline-instilled mice. The nonfibrogenic control particle, TiO2, did not elevate the levels of PKC{delta} RNA and was similar to the saline control mice. Similar to the RNA results, PKC{delta} protein levels were also found to be significantly elevated in silica-exposed mice compared with saline- and TiO2-exposed mice (4,921 ± 357 int/mm2 vs. 2,571 ± 333 int/mm2 and 1,805 ± 256 int/mm2; P ≤ 0.05, respectively; Fig. 1). These results indicate that PKC{delta} RNA and protein levels were both increased long term in AM after silica exposure in NZM mice.


View this table:
[in this window]
[in a new window]
 
Table 1. Up- and downregulated genes in AM from silica-exposed NZM mice

 


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1. Western blot analysis for PKC{delta} in alveolar macrophage cellular lysates from saline- (n = 4), TiO2- (n = 4), and silica- (n = 4) instilled New Zealand mixed (NZM) mice 14 wk after exposure. Densitometry shows a 2-fold increase in PKC{delta} levels compared with saline- and TiO2-exposed mice. Equal numbers of cells (1 x 106) were lysed, and equal concentrations of protein were added per lane. The cells were >90% alveolar macrophages. *Significant differences between silica-exposed mice and saline or TiO2 controls (P ≤ 0.01).

 
Rottlerin reduces silica-induced apoptosis of BMDM and PKC{delta} protein levels. To determine whether rottlerin could block silica-induced apoptosis of macrophages, BMDM were utilized in vitro. Apoptosis of silica-treated BMDM was determined by measuring DNA fragmentation. Figure 2 shows that 500 µg/ml silica induced a threefold increase in apoptotic cells within 8 h compared with an untreated control and was significantly reduced by the addition of rottlerin (1.074 ± 0.084 vs. 0.325 ± 0.073 vs. 0.663 ± 0.091; P ≤ 0.05, respectively). The apparent increase in DNA fragmentation by rottlerin alone was not statistically significant from control (Fig. 2). However, if cells are treated with 500 µg/ml silica for >12 h, rottlerin does not inhibit apoptosis (data not shown). These results demonstrated that rottlerin can reduce or delay apoptosis of silica-treated cells in vitro. Furthermore, PKC{delta} levels were significantly increased fivefold within 2 h after treatment with 500 µg/ml silica compared with an untreated control (1,766 ± 177 int/mm2 vs. 311 ± 13 int/mm2; P ≤ 0.001, respectively; Fig. 3). TiO2 (250 and 500 µg/ml) did not increase the levels of PKC{delta} compared with an untreated control (404 ± 93 int/mm2 and 359 ± 40 int/mm2 vs. 311 ± 13 int/mm2, respectively; Fig. 3). To inhibit PKC{delta}, rottlerin was added to the media of the BMDM culture 1 h before the addition of silica. Figure 3 demonstrates that addition of 1 µg/ml rottlerin inhibited the upregulation of PKC{delta} by silica at 2 h for the 500 µg/ml silica exposure (302 ± 40 int/mm2 vs. 1,766 ± 177 int/mm2; P ≤ 0.001, respectively). Treatment of BMDM with rottlerin alone did not have an effect on the levels of PKC{delta} at 2 h (Fig. 3).



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2. Determination of apoptosis measuring DNA fragmentation. Bone marrow-derived macrophages (BMDM) received no treatment, 500 µg/ml silica for 8 h, 500 µg/ml silica + 1 µg/ml rottlerin, or 1 µg/ml rottlerin only. Rottlerin reduced the amount of apoptosis in silica-treated BMDM at 8 h. *Significant differences between silica-treated BMDM and untreated BMDM and silica + rottlerin-treated BMDM (P ≤ 0.05). OD, optical density.

 


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3. Western blot analysis for PKC{delta} in BMDM. Cells received no treatment, 250 and 500 µg/ml TiO2, 250 and 500 µg/ml silica from 2, 4, and 8 h, 500 µg/ml silica + 1 µg/ml rottlerin for 2 h, or 1 µg/ml rottlerin only for 2 h. Silica exposure increases PKC{delta} levels within 2 h and decreases around 8 h after exposure. Densitometry shows a significant increase in the level of PKC{delta} with 500 µg/ml silica exposure at 2 h. Adding rottlerin completely inhibited the silica-induced upregulation of PKC{delta}. Equal concentrations of protein were added per lane. Shown is a representative example from 1 of 3 separate experiments. *Significant differences between silica-treated BMDM and no treatment, TiO2 treatments, silica + rottlerin treatments, or rottlerin-only treatments (P ≤ 0.001). Sil, silica; Rott, rottlerin.

 
Rottlerin treatment decreases levels of PKC{delta} in NZM mice. On the basis of the results above supporting the role of PKC{delta} in silica-induced apoptosis in vitro through the ability of rottlerin to inhibit this process, the effect of rottlerin was examined in vivo. NZM mice were exposed to saline, two instillations of 1 mg of silica, two instillations of 1 mg of silica and 10 µg of rottlerin, or 10 µg of rottlerin alone. Rottlerin instillations were given 1 day before silica instillation and then once a week for 14 wk. Similar to the results in Fig. 1, PKC{delta} levels in AM, lavaged from the lungs of silica-treated NZM mice at 14 wk, were significantly increased compared with saline control mice (2,887 ± 643 int/mm2 vs. 249 ± 44 int/mm2; P ≤ 0.001, respectively; Fig. 4). However, instillation of rottlerin once a week for 14 wk significantly decreased the levels of PKC{delta} expression in silica-treated mice compared with mice receiving only silica (606 ± 124 int/mm2 vs. 2,887 ± 643 int/mm2; P ≤ 0.001, respectively; Fig. 4). These results suggest an association between the effects of rottlerin and PKC{delta}.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4. Western blot analysis for PKC{delta} in alveolar macrophages collected from saline- (n = 5), silica- (1 mg x 2 instillations; n = 5), silica (1 mg x 2 instillations) + rottlerin- (10 µg/weekly instillation; n = 5), and rottlerin-only- (10 µg/weekly instillation; n = 5) treated NZM mice 14 wk after exposure. Silica exposure upregulated the levels of PKC{delta} 14 wk after exposure; however, weekly instillation of rottlerin reduced the levels of PKC{delta} induced by silica. Equal numbers of cells (1 x 106) were lysed, and equal concentrations of protein were loaded per lane. Cells were >90% alveolar macrophages. *Significant differences between silica exposure and saline, saline + rottlerin, or silica + rottlerin (P ≤ 0.001).

 
Rottlerin decreases severity of kidney disease in silica-treated NZM mice. Silica exposure in NZM mice has been previously reported to increase proteinuria and immune complex and complement deposition within the kidney (6). In this study, proteinuria levels >500 mg/dl were seen in three out of five (60%) of the silica-treated mice 14 wk postinstillation. However, none of the mice developed >500 mg/dl proteinuria in silica-instilled mice that were also treated with rottlerin once a week for 14 wk (Fig. 5). Proteinuria was observed in one out of five (20%) mice receiving rottlerin-only treatments (Fig. 5). Kidneys from these mice were examined for IgG immune complex and complement C3 deposition. Figure 6 shows increased IgG deposition within the glomerulus of silica-exposed mice compared with the saline control mice, similar to previously reported results (6). In contrast, silica-exposed mice receiving rottlerin instillations once a week for 14 wk showed less extensive IgG deposition within the glomerulus (Fig. 6). Similar staining patterns for complement C3 were also seen (data not shown).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5. Percentage of mice with ≥2+ proteinuria (100 mg/dl) levels in saline- (n = 5), silica- (1 mg x 2 instillations; n = 5), silica (1 mg x 2 instillations) + rottlerin- (10 µg/weekly instillation; n = 5), and rottlerin-only- (10 µg/weekly instillation; n = 5) treated NZM mice 14 wk after exposure as measured by the use of ChemStrip 2GP glucose/proteinuria strips. There was a significant difference between silica-exposed mice and saline-exposed mice in the development of proteinuria (P ≤ 0.05 by Kaplan-Meier log-rank test). However, there were no statistically significant differences between the silica-treated mice and the silica + rottlerin-treated mice (P = 0.083 by Kaplan-Meier log-rank test).

 


View larger version (167K):
[in this window]
[in a new window]
 
Fig. 6. Representative examples of immunohistochemical staining of kidney sections for IgG deposition from saline- (A, n = 5), silica- (B, n = 5), saline + rottlerin- (C, 10 µg/weekly instillation), and silica (1 mg x 2 instillations) + rottlerin- (D, 10 µg/weekly instillation) treated NZM mice 14 wk after exposure. A goat anti-mouse IgG-FITC antibody was used to stain for IgG deposition within the kidney. The silica-exposed mice showed IgG deposition within the glomeruli (B); however, weekly rottlerin instillations reduced the silica-induced complement and IgG deposition (D). Saline- and rottlerin-only instilled mice showed almost no staining for IgG. Similar staining patterns were seen for complement C3 (data not shown). Shown is a representative example of 1 out of 5 mice/group. Magnification, x60.

 
Rottlerin decreases the level of anti-histone autoantibodies in NZM mice. As previously reported, silica exposure in NZM mice results in a significant increase in the levels of anti-nuclear autoantibodies, with an increase in anti-histone autoantibodies being the most prominent (6). We therefore tested the ability of rottlerin in vivo to affect this indicator of autoimmune disease. A significant increase in anti-histone autoantibodies was observed in silica-exposed NZM mice at 14 wk compared with saline control mice (0.392 ± 0.086 vs. 0.187 ± 0.034; P ≤ 0.05, respectively; Fig. 7). However, instillation of rottlerin significantly decreased the levels of anti-histone autoantibodies within silica-exposed NZM mice compared with mice that received only silica (0.159 ± 0.045 vs. 0.392 ± 0.086; P ≤ 0.05, respectively; Fig. 7). Consequently, rottlerin was effective in blocking the silica-induced increase in anti-histone autoantibodies.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7. Development of anti-histone autoantibodies in saline- (n = 5), silica- (1 mg x 2 instillations; n = 5), silica (1 mg x 2 instillations) + rottlerin- (10 µg/weekly instillation; n = 5), and rottlerin-only- (10 µg/weekly instillation; n = 5) treated NZM mice 14 wk after exposure as measured by ELISA. Silica exposure significantly elevated the levels of anti-histone autoantibodies in NZM mice 14 wk after silica exposure. However, weekly instillations of rottlerin in silica-instilled mice inhibited the development of high levels of anti-histone autoantibodies. The values reported are mean OD values for each treatment group. *Significant differences between silica-exposed mice and saline- or silica + rottlerin-exposed mice (P ≤ 0.05).

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Silica exposure has been reported to induce autoimmune responses and is associated with an increased incidence of systemic autoimmune disease (2, 25, 26). However, the mechanisms leading to these autoimmune responses are not understood. Elucidating these mechanisms may provide a better understanding of other environmentally relevant exposures implicated in triggering autoimmune responses as well as providing direction for novel therapies.

Possible mechanisms of silica-induced autoimmune disease may involve the AM, an immune cell of the lung that is the first line of defense. It has previously been reported that silica exposure leads to a caspase-dependent apoptosis of AM (19, 34). Silica-induced apoptosis of AM leads to release and uptake of silica by other AM, producing a cyclical process of inflammation and cell death (10). This constant inflammation and cellular death may provide excess antigen that is being presented to the immune system, thereby breaking immune tolerance.

Studies by Rosen and Casciola-Rosen (30) have reported concentrated autoantigens within the blebs of apoptotic cells. Lupus autoantigens are represented by structures that are chemically cleaved or modified during apoptosis, and if this material is not removed by noninflammatory processes, apoptotic material could be presented by specialized antigen-presenting cells to induce immune responses (29, 35). In an in vitro system, macrophages were found to prevent immunity to apoptotic material by competing with dendritic cells for uptake of apoptotic blebs, demonstrating the importance of the cell population silica is targeting for injury (1). Consistent with this hypothesis, mice intravenously exposed to apoptotic cellular material have been reported to develop autoantibodies (24).

In this study, a cDNA microarray specific for mouse toxicology and immunology genes was used with RNA from AM collected from silica-exposed NZM mice to analyze for expression changes in genes involved in the apoptotic process. Silica exposure in NZM mice induced several genes involved in apoptosis, including thymosin {beta}10, PKC{delta}, TNF-{alpha}-induced protein-6, and Bcl-2-like protein. The apoptosis-related functions of these genes are reviewed in Brown et al. (8). In this study, we focused on the possible role PKC{delta} could play in silica-induced apoptosis and autoimmune disease. PKC{delta} was increased after silica exposure in vivo and remained increased long term, possibly through release of TNF-{alpha} (13). Concurrent with this hypothesis, we have previously reported a significant increase in TNF-{alpha} levels within the lung lavage fluid of silica-treated NZM mice 14 wk after silica exposure (7).

By measuring DNA fragmentation, we observed that silica induced apoptosis of BMDM, and this process could be delayed by the addition of rottlerin. Silica exposure has previously been reported to induce mitochondrial cytochrome c release, leading to a caspase-mediated apoptosis of macrophages (34). Furthermore, PKC{delta} has been reported to migrate to the mitochondria after exposure to asbestos and H2O2, resulting in altered mitochondrial membrane permeability, thereby activating caspases (23, 32). Therefore, it appears silica could induce apoptosis by multiple pathways and that rottlerin can delay the onset of apoptosis in macrophages. However, it remains controversial as to whether rottlerin is able to inhibit apoptosis through PKC{delta}. Soltoff (33) recently reported that rottlerin is a mitochondrial uncoupler and decreases cellular ATP levels, thereby indirectly affecting PKC{delta} activation. However, in our model, rottlerin ultimately did reduce apoptosis of silica-treated macrophages, but it remains unclear if this was mediated through PKC{delta}.

To test our hypothesis that in vivo treatment with rottlerin could significantly affect the exacerbation of systemic autoimmune disease by silica, we utilized weekly intranasal instillations of rottlerin to reduce silica-induced apoptosis. We have previously reported that intranasal instillation of silica in autoimmune-prone NZM mice results in a significant exacerbation of autoimmunity 14 wk after instillation as measured by increases in mortality, proteinuria, autoantibodies, and glomerulonephritis (6). NZM mice were chosen for these studies because they typically do not develop high levels of autoantibodies and glomerulonephritis until around 6 mo of age, thereby allowing us to observe any disease acceleration due to silica exposure (31). After silica exposure, NZM mice developed high levels of autoantibodies, and severe immune complex and complement deposition took place within the kidney around 14 wk (6, 31). Similar to the results previously reported, NZM mice in this study that received only silica instillations developed high proteinuria (60% of the mice), high levels of anti-histone autoantibodies, and excess immune complex and complement C3 deposition in the kidneys (6). However, silica-exacerbated systemic autoimmune disease was significantly reversed with weekly rottlerin instillations. Silica-exposed NZM mice receiving weekly instillations of rottlerin did not develop high levels of proteinuria, anti-histone autoantibodies, or severe immune complex or complement C3 deposition within the kidney.

Together, these data demonstrate that in vivo treatment with rottlerin significantly decreased the exacerbation of systemic autoimmune disease by silica exposure. Because of the role of PKC{delta} in apoptosis, it is tempting to speculate that this effect was due to inhibition of apoptosis. It would be interesting to test the effect of pan-caspase inhibitors in this model, but such a study is complicated by the myriad of cellular effects of the caspases, including posttranslational modification of cytokines. Since the exact cellular function(s) of rottlerin are also not entirely clear, an in vivo demonstration of a role of apoptosis inhibition in reducing silica-induced autoimmune disease is very challenging. This study demonstrates an important protective effect of rottlerin in systemic autoimmune disease in this model and sets the stage for future studies on its role in immune modification, possibly with therapeutic implications.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by National Institutes of Health Grant ES-04084, COBRE National Center for Research Resources Grant P20-RR-17670, and an American Foundation for Pharmaceutical Education Fellowship (to J. M. Brown).


    FOOTNOTES
 

Address for reprint requests and other correspondence: A. Holian, Center for Environmental Health Sciences, SB154, Dept. of Biomedical and Pharmaceutical Sciences, Univ. of Montana, Missoula, MT 59812 (e-mail: andrij.holian{at}umontana.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, and Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via {alpha}v{beta}5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188: 1359–1368, 1998.[Abstract/Free Full Text]
  2. American Thoracic Society Committee of the Scientific Assembly on Environmental and Occupational Health. Adverse effects of crystalline silica exposure. Am J Respir Crit Care Med 155: 761–768, 1997.[ISI][Medline]
  3. Bertho N, Blancheteau VM, Setterblad N, Laupeze B, Lord JM, Drenou B, Amiot L, Charron DJ, Fauchet R, and Mooney N. MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-{delta} isoenzyme. Int Immunol 14: 935–942, 2002.[Abstract/Free Full Text]
  4. Brodie C and Blumberg PM. Regulation of cell apoptosis by protein kinase C{delta}. Apoptosis 8: 19–27, 2003.[CrossRef][ISI][Medline]
  5. Brody AR, Roe MW, Evans JN, and Davis GS. Deposition and translocation of inhaled silica in rats. Quantification of particle distribution, macrophage participation, and function. Lab Invest 47: 533–542, 1982.[ISI][Medline]
  6. Brown JM, Archer AJ, Pfau JC, and Holian A. Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 131: 415–421, 2003.[CrossRef][ISI][Medline]
  7. Brown JM, Pfau JC, and Holian A. Immunoglobulin and lymphocyte responses following silica exposure in New Zealand mixed mice. Inhal Toxicol 16: 133–139, 2004.[CrossRef][ISI][Medline]
  8. Brown JM, Pfau JC, Pershouse MA, Holian A. Silica, apoptosis, and autoimmunity. J Immunotox 1: 177–188, 2004.
  9. Chao SK, Hamilton RF, Pfau JC, and Holian A. Cell surface regulation of silica-induced apoptosis by the SR-A scavenger receptor in a murine lung macrophage cell line (MH-S). Toxicol Appl Pharmacol 174: 10–16, 2001.[CrossRef][ISI][Medline]
  10. Cooper GS, Miller FW, and Germolec DR. Occupational exposures and autoimmune diseases. Int Immunopharmacol 2: 303–313, 2002.[CrossRef][ISI][Medline]
  11. Davies SP, Reddy H, Caivano M, and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95–105, 2000.[CrossRef][ISI][Medline]
  12. Doll NJ, Stankus RP, Hughes J, Weill H, Gupta RC, Rodriguez M, Jones RN, Alspaugh MA, and Salvaggio JE. Immune complexes and autoantibodies in silicosis. J Allergy Clin Immunol 68: 281–285, 1981.[CrossRef][ISI][Medline]
  13. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, and Kufe D. Proteolytic activation of protein kinase C{delta} by an ICE-like protease in apoptotic cells. EMBO J 14: 6148–6156, 1995.[Abstract]
  14. Gabler C, Kalden JR, and Lorenz HM. The putative role of apoptosis-modified histones for the induction of autoimmunity in systemic lupus erythematosus. Biochem Pharmacol 66: 1441–1446, 2003.[CrossRef][ISI][Medline]
  15. Greidinger EL. Apoptosis in lupus pathogenesis. Front Biosci 6: D1392–D1402, 2001.[ISI][Medline]
  16. Gschwendt M. Protein kinase C{delta}. Eur J Biochem 259: 555–564, 1999.[CrossRef][ISI][Medline]
  17. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, and Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199: 93–98, 1994.[CrossRef][ISI][Medline]
  18. Hamilton RF, de Villiers WJ, and Holian A. Class A type II scavenger receptor mediates silica-induced apoptosis in Chinese hamster ovary cell line. Toxicol Appl Pharmacol 162: 100–106, 2000.[CrossRef][ISI][Medline]
  19. Iyer R, Hamilton RF, Li L, and Holian A. Silica-induced apoptosis mediated via scavenger receptor in human alveolar macrophages. Toxicol Appl Pharmacol 141: 84–92, 1996.[CrossRef][ISI][Medline]
  20. Kikkawa U, Matsuzaki H, and Yamamoto T. Protein kinase C{delta} (PKC{delta}): activation mechanisms and functions. J Biochem (Tokyo) 132: 831–839, 2002.[Abstract]
  21. Lorenz HM, Herrmann M, Winkler T, Gaipl U, and Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 5: 443–449, 2000.[CrossRef][ISI][Medline]
  22. Lounsbury KM, Stern M, Taatjes D, Jaken S, and Mossman BT. Increased localization and substrate activation of protein kinase C{delta} in lung epithelial cells following exposure to asbestos. Am J Pathol 160: 1991–2000, 2002.[Abstract/Free Full Text]
  23. Majumder PK, Mishra NC, Sun X, Bharti A, Kharbanda S, Saxena S, and Kufe D. Targeting of protein kinase C{delta} to mitochondria in the oxidative stress response. Cell Growth Differ 12: 465–470, 2001.[Abstract/Free Full Text]
  24. Mevorach D, Zhou JL, Song X, and Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 188: 387–392, 1998.[Abstract/Free Full Text]
  25. Parks CG, Conrad K, and Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107: 793–802, 1999.[ISI][Medline]
  26. Parks CG, Cooper GS, Nylander-French LA, Sanderson WT, Dement JM, Cohen PL, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Hoppin JA, and Savitz DA. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 46: 1840–1850, 2002.[CrossRef][ISI][Medline]
  27. Pfau JC, Brown JM, and Holian A. Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology 195: 167–176, 2004.[CrossRef][ISI][Medline]
  28. Pongracz J, Webb P, Wang K, Deacon E, Lunn OJ, and Lord JM. Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein kinase C-{delta}. J Biol Chem 274: 37329–37334, 1999.[Abstract/Free Full Text]
  29. Ronchetti A, Iezzi G, Crosti MC, Garancini MP, Protti MP, and Bellone M. Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. J Leukoc Biol 66: 247–251, 1999.[Abstract]
  30. Rosen A and Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 6: 6–12, 1999.[CrossRef][ISI][Medline]
  31. Rudofsky UH and Lawrence DA. New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect 107, Suppl 5: 713–721, 1999.[ISI][Medline]
  32. Shukla A, Stern M, Lounsbury KM, Flanders T, and Mossman BT. Asbestos-induced apoptosis is protein kinase C{delta}-dependent. Am J Respir Cell Mol Biol 29: 198–205, 2003.[Abstract/Free Full Text]
  33. Soltoff SP. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase C{delta} tyrosine phosphorylation. J Biol Chem 276: 37986–37992, 2001.[Abstract/Free Full Text]
  34. Thibodeau M, Giardina C, and Hubbard AK. Silica-induced caspase activation in mouse alveolar macrophages is dependent uponmitochondrial integrity and aspartic proteolysis. Toxicol Sci 76: 91–101, 2003.[Abstract/Free Full Text]
  35. Utz PJ and Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 41: 1152–1160, 1998.[CrossRef][ISI][Medline]
  36. Warheit DB, Carakostas MC, Bamberger JR, and Hartsky MA. Complement facilitates macrophage phagocytosis of inhaled iron particles but has little effect in mediating silica-induced lung inflammatory and clearance responses. Environ Res 56: 186–203, 1991.[CrossRef][ISI][Medline]
  37. Warheit DB, Hansen JF, and Hartsky MA. Physiological and pathophysiological pulmonary responses to inhaled nuisance-like or fibrogenic dusts. Anat Rec 231: 107–118, 1991.[CrossRef][ISI][Medline]
  38. Webb PR, Wang KQ, Scheel-Toellner D, Pongracz J, Salmon M, and Lord JM. Regulation of neutrophil apoptosis: a role for protein kinase C and phosphatidylinositol-3-kinase. Apoptosis 5: 451–458, 2000.[CrossRef][ISI][Medline]
  39. Wilke RA, Salisbury S, Abdel-Rahman E, and Brazy PC. Lupus-like autoimmune disease associated with silicosis. Nephrol Dial Transplant 11: 1835–1838, 1996.[ISI][Medline]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
289/6/L990    most recent
00078.2005v1
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Brown, J. M.
Articles by Holian, A.
PubMed
PubMed Citation
Articles by Brown, J. M.
Articles by Holian, A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.